Complete and Partial Breast Cancer Remission

How the absence or reduction of cancer directs treatment and care

Breast cancer treatment may result in complete or partial remission. Complete remission is when physical exams, blood tests, and imaging do not show any signs of cancer in your body. Partial remission occurs when the tumor is still present, but it is substantially reduced.

Healthcare providers use the term remission rather than cure because there remains a possibility that breast cancer may return after it's treated. This is called a recurrence.

This article reviews the different types of remission and the approach to their treatment and management.

Breast Cancer Discussion Guide

Get our printable guide for your next doctor's appointment to help you ask the right questions.

Doctor Discussion Guide Old Woman

How Remission Is Determined

Breast cancer remission is determined in multiple ways including the following: 

  • Physical examination 
  • Blood tests 
  • Tissue evaluation
  • Imaging studies (such as a breast MRI or PET/CT scan)

As valuable as these tests are, they have their limitations.

Complete Remission

Complete remission, also known as a complete response, means that cancer appears to be gone after treatment.

Even after complete remission has been declared, there may still be cancer cells below the detection levels of these tests. Some cancer cells may lie dormant indefinitely; others may suddenly multiply months or years later, resulting in a recurrence.

Because of the potential for recurrence, many healthcare providers will refer to complete remission as no evidence of disease, or NED.

Senior cancer patient talks with her doctor
FatCamera / Getty Images

Partial Remission

If breast cancer is in partial remission, also known as a partial response, it means that the solid tumor has shrunk. Partial remission is usually declared when there is at least a 50% reduction in the tumor size or the number of cancer cells from the baseline value.

Partial remission is not the usual goal of breast cancer treatment. It is only when a tumor is inoperable or has metastasized (spread to other organs) that an oncologist will aim to control the tumor rather than eradicate it.

In all but stage IV breast cancer, efforts will be made to remove the tumor and use radiation and/or chemotherapy to get rid of all remaining cancer cells.

To qualify as a complete or partial remission, the absence or reduction of cancer must last for at least one month. The absence of symptoms is neither a measure nor an indication of remission.


For those in complete remission, your healthcare providers will continue to monitor you closely so they can quickly identify and treat a recurrence if needed. You may also require maintenance therapy after the initial treatment. 

The goal of maintenance therapy for those in complete remission is to prevent or delay recurrence. For those in partial remission, the goal is to slow the growth or to lengthen a person’s life. In advanced-stage cancer, it may decrease symptoms or increase quality of life.

Maintenance medication may include a lower dose of chemotherapy, targeted therapy, or endocrine (hormone) therapy. 


One of the most common types of maintenance therapy often involves traditional chemotherapy drugs. Often, they are given in a lower dose and as a single medication rather than in combination to help decrease side effects.

Targeted Therapy

Targeted therapy includes kinase inhibitors, monoclonal antibodies, or antibody-drug conjugates.

Kinase inhibitors block a protein that keeps cancer cells from growing and include:

  • Tykerb (lapatinib)
  • Nerlynx (neratinib)
  • Tukysa (tucatinib)

Monoclonal antibodies help boost the immune system. Examples include:

  • Herpecitin (trastuzumab)
  • Perjeta (pertuzumab)
  • Margenza (margetuximab)
  • Phesgo (trastuzumab, pertuzumab, and hyaluronidase)

Antibody-drug conjugates combine monoclonal antibodies and chemotherapy and include medications such as:

  • Kadcyla (ado-trastuzumab emtansine)
  • Enhertu (fam-trastuzumab deruxtecan)

Endocrine or Hormone Therapy 

Hormone receptor-positive tumors feed off hormones and typically require endocrine therapy that blocks or stops estrogen production. While this is not a complete list, some common hormone therapy medications include:

  • Nolvadex or Soltamox (tamoxifen) 
  • Toremifene (Fareston)
  • Arimidex (anastrozole) 
  • Femara (letrozole)
  • Faslodex (fulvestrant)
  • Zoladex (goserelin) 
  • Lupron (leuprolide)

Early-Stage Breast Cancer

If you've been diagnosed with early-stage breast cancer, you would receive local treatment that's intended to completely eradicate the disease.

Partial remission is a term that is usually used to describe stage IV metastatic breast cancer treatment response, but, sometimes, partial remission may also apply to earlier stages.

Even if you are in complete remission, you may still need to take medication to keep your cancer from returning. Known as adjuvant therapy, the drugs are primarily for estrogen receptor-positive breast cancer. This is a type of cancer whose growth is directly influenced by the hormone estrogen.

To reduce the risk of recurrence, your healthcare provider may prescribe drugs that suppress either the production of estrogen or the stimulation of estrogen-sensitive cells.

If you have estrogen-sensitive cancer, your practitioner may prescribe tamoxifen, which binds to the estrogen receptors on cells. After three to five years, you may be switched to another class of drug known as aromatase inhibitors (AIs).

For post-menopausal women, you may be prescribed an aromatase inhibitor for an additional five years. Your healthcare provider may make this change to avoid the long-term side effects of tamoxifen. Aromatase inhibitors block estrogen production in the liver, pancreas, breasts, brain, and other tissues.

Unlike tamoxifen, aromatase inhibitors are only effective in postmenopausal women or women whose ovaries are suppressed.

If your breast cancer is estrogen-receptor-negative, you may not need any medications. 

Metastatic Breast Cancer

If you have stage IV breast cancer, you will be prescribed medications to better control the disease. While treatable, metastatic breast cancer cannot be cured. 

With that being said, recent advances in chemotherapy and immunotherapy have allowed people with stage IV cancer to live longer without symptoms of the disease. This includes experimental adoptive cell therapy (ACT) in which your body's own cancer-fighting cells are harvested and cultured for use as immunotherapy.


When breast cancer is treated, it may result in complete or partial remission. Complete remission occurs when physical exams, blood tests, and imaging do not show any signs of cancer. Partial remission is when the tumor is still present but reduced.

Those with breast cancer will be monitored by their healthcare team for years to come. Maintenance or continued treatment depends on the type of cancer, stage, and size. Some require targeted therapy while others need endocrine (hormone) therapy or continued chemotherapy.

A Word From Verywell

After any breast cancer diagnosis, you will need to see an oncologist on an ongoing basis to monitor your condition. This typically involves a healthcare provider's visit every few months for the first five years, after which you may only need yearly appointments. You will also need an annual mammogram and possibly a breast MRI unless you've had a bilateral mastectomy.

Although there is no way to definitively prevent breast cancer recurrence, there are preventive medications that reduce the risk of a recurrence for some types of breast cancer. By remaining linked to medical care, you will increase the chances that a recurrence will be caught early when it is most treatable.

Frequently Asked Questions

  • How often is maintenance therapy given?

    Maintenance therapy can continue for weeks, months, or years. The length is based on the type of cancer, the medication, efficacy (how well it works), and side effects.

  • How long can you be on maintenance chemotherapy?

    According to the American Cancer Society, there is no time limit. It depends on multiple factors including how you tolerate treatment and the type of cancer you have. If the treatment stops working or causes severe side effects, your healthcare provider may change your medications.

  • Does maintenance therapy cause hair loss?

    While hair loss does not occur with all maintenance therapy, it is a possibility with certain medications. Some medications may cause your hair to change colors or become curly. Others can make your hair dry, thin, or brittle. This is very specific to the medication and how your body reacts to it.

  • What type of breast cancer is most likely to recur?

    Estrogen-receptor negative (triple-negative or HER2 - positive) breast cancer has a higher risk of early recurrence. This means within the first five years of diagnosis. Estrogen-receptor-positive tumors have a higher chance of later recurrence (after five years). Other risk factors of recurrence include larger tumors, lymph node involvement, younger age, more aggressive (higher grade) tumors, and type of initial treatment.

11 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. National Cancer Institute. Understanding cancer prognosis.

  2. American Society of Clinical Oncology (ASCO). Understanding maintenance therapy.

  3. American Cancer Society. Managing cancer as a chronic illness.

  4. American Cancer Society. Treatment of stage IV (metastatic) breast cancer.

  5. American Cancer Society. Targeted drug therapy for breast cancer.

  6. Treatments for hormone receptor-positive breast cancer.

  7. American Cancer Society. Treatment of breast cancer stages I-III.

  8. Cancer Research UK. Hair loss, hair thinning and cancer drugs.

  9. American Cancer Society. Targeted therapy side effects.

  10. Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836-1846. doi:10.1056/NEJMoa1701830.

  11. Rueda O, Sammut S, Seoane J, et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567:399-404. doi:10.1038/s41586-019-1007-8.

By Brandi Jones, MSN-ED RN-BC
Brandi is a nurse and the owner of Brandi Jones LLC. She specializes in health and wellness writing including blogs, articles, and education.

Originally written by Pam Stephan
Pam Stephan is a breast cancer survivor.
Learn about our editorial process